2. Subject is diagnosed with pulmonary arterial hypertension (WHO Group I, by right heart catheterization (RHC), mean PA pressure > 25 and PCWP < 15) and planning to start therapy with ambrisentan, either as de-novo monotherapy or as part of combination therapy.